Related Experiment Videos
Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status
S D Mayes1, D L Crites, E O Bixler
1Department of Psychiatry, Milton S. Hershey Medical Center, Hershey, PA 17033.
Insights
Methylphenidate effectively treats attention deficit hyperactivity disorder (ADHD) in preschoolers. Significant improvements were observed in children with ADHD alone and those with co-existing neurodevelopmental disorders.
Area of Science:
- Child and Adolescent Psychiatry
- Neurodevelopmental Disorders
- Pharmacological Treatments
Background:
- Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
- Methylphenidate is a widely prescribed stimulant medication for ADHD.
- Understanding treatment response in diverse pediatric populations is crucial.
Purpose of the Study:
- To evaluate the efficacy of methylphenidate in preschool-aged children with ADHD.
- To compare methylphenidate response rates in children with ADHD alone versus those with comorbid neurodevelopmental disorders.
Main Methods:
- A blind methylphenidate trial was conducted.
- Sixty-nine children diagnosed with ADHD participated.
- Participants were categorized into two groups: ADHD alone (n=36) and ADHD with additional neurodevelopmental disorders (n=33).
Main Results:
- 88% of children with ADHD alone showed significant improvement with methylphenidate.
- A 69% significant improvement rate was observed in children with ADHD and comorbid neurodevelopmental disorders.
- No significant difference in response rates was found between the two groups.
Conclusions:
- Methylphenidate is an effective treatment for preschool-aged children with ADHD.
- The presence of co-existing neurodevelopmental disorders does not significantly alter methylphenidate's efficacy in this age group.
- Findings support the use of methylphenidate for a broad range of preschool children with ADHD.
Abstract:
Sixty-nine children with attention deficit hyperactivity disorder (ADHD) underwent blind methylphenidate trials. 36 had ADHD alone (with or without a learning disability) and 33 had additional neurodevelopmental disorders. Of the children with ADHD alone, 88 per cent improved significantly on methylphenidate. This did not differ significantly from the 69 per cent response rate for children with ADHD and other neurodevelopmental disorders. The results confirm and add to the research literature indicating that ADHD children who are of preschool age and/or who have co-existing neurological disorders may benefit from methylphenidate.